Status:
COMPLETED
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
Lead Sponsor:
Patrice Perron
Collaborating Sponsors:
Theramed co.
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To compare the hypothyroid state in patients with thyroid cancer prepared either by placebo or L-T3 following L-T4 withdrawal in preparation for whole body scintigraphy. To evaluate the time needed fo...
Detailed Description
Patients with well differentiated thyroid cancer (DTC) need whole-body scintigraphy (WBS) and thyroglobulin (Tg) measurement in order to detect recurrence. Classically, withdrawal from levothyroxine (...
Eligibility Criteria
Inclusion
- Patients with well-differentiated thyroid cancer, with total thyroidectomy
- 18 y.o. or older
Exclusion
- Use of rhTSH for Whole Body Scintigraphy preparation
- Non stable cardiac arrythmias
- Any condition impairing TSH elevation(glucocorticoid use, hypopituitarism)
- Allergy to Liothyronine
- Inability to give a consent
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2005
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00223158
Start Date
September 1 2003
End Date
May 1 2005
Last Update
April 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4